Currently Browsing CPLRG™ by: Case Number
Browse By: Case Date | Case Name

  1. Pages:
  2. 1
  3. ...
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17

CPLRG™ 0068 - Therasense, Inc. v. Becton, Dickinson & Co. - May. 25, 2011

Therasense, Inc. v. Becton, Dickinson & Co., — F.3d —-, 2011 U.S. App. LEXIS 10590 (Fed. Cir. 2011) (en banc) (RADER, Newman, Lourie, Linn, Moore & Reyna; O’MALLEY, concurring-in-part & dissenting-in-part; BRYSON, Gajarsa, Dyk & Prost, dissenting) Therasense.05252011.fc

MAJOR ISSUES: inequitable conduct rendering patents unenforceable; raising standards for materiality and intent; “but for” materiality; no “sliding scale”; no materiality required for affirmative egregious misconduct

COMMENTS: In a milestone decision, the Federal Circuit, sitting en banc, reviewed the standard of materiality for the inequitable conduct defense to patent infringement. In a majority opinion for six of the participating eleven judges, Chief Judge Rader “tighten[ed] the standards for finding both intent and materiality in order to redirect a doctrine that has been overused to the detriment of the public.”  On intent, the majority (1) rejected a “sliding scale” approach under which “a weak showing of intent may be found sufficient based on a strong showing of materiality, and vice versa,” and (2) restricted the circumstances under which the necessary intent to deceive the PTO may be inferred.  On materiality, the majority (1) adopted a “but-for” standard of materiality, (2) recognized “an exception in cases of affirmative egregious misconduct,” and (3) eschewed prior decisions that relied on the PTO’s Rule 56 definitions of materiality.

For a preliminary, critical evaluation of Therasense, see below.

CROSS REFERENCES:  On the inequitable conduct defense and its history, see Chisum on Patents 19.03.  For case law on the defense, see Chisum, Patent Law Digest 4000.

Read CPLRG™ 0068

CPLRG™ 0069 - Microsoft Corp. v. i4i Limited Partnership - Jun. 9, 2011

Microsoft Corp. v. i4i Limited Partnership, — U.S. —- (June 9, 2011) (SOTOMAYOR, Scalia, Kennedy, Ginsburg, Breyer, Alito, & Kagan; BREYER, Scalia & Alito, concurring; THOMAS, concurring judgment) Microsofti4i.ussc

MAJOR ISSUES: invalidity defenses; clear and convincing evidence standard of proof; Section 282 as codification of common-law heightened proof standard; jury instruction when accused infringer relies on new evidence not considered by PTO during examination

COMMENTS: The Court, in a well-crafted opinion by Justice Sotomayor, confirms the Federal Circuit’s position, consistently maintained for almost 30 years, that one challenging the validity of a patent claim bears a proof burden of clear and convincing evidence and not the general civil burden of a preponderance of the evidence. This heightened standard is not lowered even when the challenger relies on “new” evidence, that is, evidence that was not presented to or considered by the PTO during examination of the claim. However, the Court, like the Federal Circuit, cautioned that a challenger may more easily carry the heightened burden by relying on new evidence. And the Court directed that a cautionary instruction to a jury on new evidence will be proper.

Cross References: For a discussion of the proof burden, as applied to obviousness invalidity defenses, see Chisum on Patents § 5.06[2]. See also Chisum on Patents § 19.02. For cases on the presumption of validity, see Chisum Patent Law Digest § 1562, § 5663.

For a summary of the Court’s decision, see below. Read CPLRG™ 0069

CPLRG™ 0070 - Board of Trustees of the Leland Stanford Junior Univ. v. Roche Molecular Sys. - Jun. 6, 2011

Board of Trustees of the Leland Stanford Junior Univ. v. Roche Molecular Sys., 131 S. Ct. 2188 (June 6, 2011) (ROBERTS, Scalia, Kennedy, Thomas, Alito & Kagan; SOTOMAYOR, concurring; BREYER & Ginsburg, dissenting) StanfordUniversityv.RocheMolecular06062011

MAJOR ISSUES: ownership of inventions and patent rights; initial ownership vesting in inventor; employee inventions; federally-funded inventions; universities as federal contractors

“Since 1790, the patent law has operated on the premise that rights in an invention belong to the inventor.” Read CPLRG™ 0070

CPLRG™ 0071 - Prometheus Laboratories, Inc. v. Mayo Collaborative Services - Dec. 17, 2010

Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 628 F.3d 1347 (Fed. Cir. 2010) (LOURIE, Rader & Bryson), on remand from 130 S. Ct. 3543 (2010), cert. granted, 180 L. Ed. 2d 844 (June 20, 2011). PrometheusLabMayo12172010.fc

MAJOR ISSUES: Section 101 patent eligible subject matter; Bilski; medical diagnostic claims

In 2009, before the Supreme Court’s Bilski decision on patent eligible subject matter and abstract ideas, see Bilski v. Kappos, 130 S. Ct. 3218, CPLRG 0015 (2010), the Federal Circuit held that medical diagnostic claims were to patent eligible subject matter. The Supreme Court remanded the case for reconsideration in light of Bilski.  The Federal Circuit reaffirmed its prior decision.  On June 20, 2011, the Supreme Court granted review, indicating the Supreme Court’s intent to address again issues on what constitutes patent eligible subject matter under Section 101, this time in regard to biomedical subject matter. Read CPLRG™ 0071

CPLRG™ 0072 - Research Corp. Technologies, Inc. v. Microsoft Corp - Dec. 8, 2010

Research Corp. Technologies, Inc. v. Microsoft Corp., 627 F.3d 859 (Fed. Cir. 2010) (RADER, Newman & Plager) ResearchCorp12082010

In an early response to Bilski v. Kappos, 130 S. Ct. 3218, CPLRG 0015 (2010), the Federal Circuit, in an opinion by Chief Judge Rader, rebuffed a Section 101 challenge to claims in two patents to methods of “digital image halftoning.”  The court indicated a reluctance to find the kind of abstractness that the Supreme Court relied upon in Bilski to reject claims as ineligible subject matter under Section 101.  The court suggested that it would be more fruitful to apply specific standards of patentability, such as indefiniteness and lack of written description under 35 U.S.C. Section 112.

The struggle to make sense out of Bilski continued in subsequent Federal Circuit decisions.  See, e.g., Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 628 F.3d 1347, CPLRG 0071 (Fed. Cir. 2010), on remand from 130 S. Ct. 3543 (2010), cert. granted, 180 L. Ed. 2d 844 (June 20, 2011); Ass’n for Molecular Pathology v. United States Patent and Trademark Office, CPLRG 0073 (Fed. Cir. July 29, 2011); Cybersource Corp. v. Retailed Decisions, Inc., CPLRG 0074 (Fed. Cir. Aug. 16, 2011). Read CPLRG™ 0072

Currently Browsing CPLRG™ by: Case Number
Browse By: Case Date | Case Name

  1. Pages:
  2. 1
  3. ...
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17

©2010 Donald S. Chisum - All Rights Reserved

Website design by Bluegrass Internet Services